Intercept’s fatty liver drug one step closer to approval
Intercept Pharmaceuticals has announced that its treatment in patients with a progressive fatty liver disease showed an improvement in scarring on the organ.
Read More
Tag: obeticholic acid
FDA warning on Intercept’s Ocaliva after patient deaths
US regulators have issued a safety communication warning of the risk for serious liver injury and death from incorrect dosing of Intercept Pharmaceuticals’ Ocaliva in patients with primary biliary cholangitis.
Read More
Four new medicines win nod for NHS Scotland
The Scottish Medicines Consortium has accepted four new medicines for routine use by NHS Scotland, offering patients new options for kidney cancer, liver disease and the prevention of nausea and vomiting.
Read More
Ocalvia gets NHS green light for rare chronic liver disease
Intercept’s Ocaliva has been issued a final green light for use by the NHS to treat the rare chronic liver disease primary biliary cholangitis (PBC), which affects around one in 1,000 women over the age of 40 but is still the leading cause of liver transplantation in adult women in the UK.
Read More
EU approves new therapy for rare liver condition PBC
The European Commission has cleared Intercept’s Ocaliva for the treatment of primary biliary cholangitis (PBC), giving patients the potential to access the first new therapy for the condition in nearly 20 years.
Read More
Eight medicines win CHMP nod
Eight medicines have taken a big leap towards being approved in Europe having won the support of the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
